(Q38020428)

27 August 2017

title

Radionuclide therapy of adrenal tumors (English)

1 reference

27 August 2017

Jorge A Carrasquillo

1

1 reference

27 August 2017

Neeta Pandit-Taskar

series ordinal

2

1 reference

27 August 2017

Clara C Chen

series ordinal

3

1 reference

27 August 2017

publication date

20 June 2012

1 reference

Journal of Surgical Oncology

27 August 2017

published in

1 reference

27 August 2017

volume

106

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

632-642

1 reference

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters

27 August 2017

cites work

1 reference

Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells

21 January 2018

1 reference

Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C).

21 January 2018

1 reference

Molecular imaging of neuroendocrine tumors

21 January 2018

1 reference

Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience

21 January 2018

1 reference

Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.

21 January 2018

1 reference

The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription

21 January 2018

1 reference

A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin.

21 January 2018

1 reference

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

21 January 2018

1 reference

Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy.

21 January 2018

1 reference

No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.

21 January 2018

1 reference

Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

21 January 2018

1 reference

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

21 January 2018

1 reference

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

21 January 2018

1 reference

Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.

21 January 2018

1 reference

Suppression of thyroid radioiodine uptake by various doses of stable iodide

21 January 2018

1 reference

Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout

21 January 2018

1 reference

Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine

21 January 2018

1 reference

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma

21 January 2018

1 reference

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation

21 January 2018

1 reference

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

21 January 2018

1 reference

The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms

21 January 2018

1 reference

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors

21 January 2018

1 reference

(131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome

21 January 2018

1 reference

Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response

21 January 2018

1 reference

Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases

21 January 2018

1 reference

Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy

21 January 2018

1 reference

First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma

21 January 2018

1 reference

Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma.

21 January 2018

1 reference

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy

21 January 2018

1 reference

131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma

21 January 2018

1 reference

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

21 January 2018

1 reference

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

21 January 2018

1 reference

Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.

21 January 2018

1 reference

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma

21 January 2018

1 reference

Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma

21 January 2018

1 reference

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

21 January 2018

1 reference

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

21 January 2018

1 reference

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients

21 January 2018

1 reference

Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience

21 January 2018

1 reference

[131I]MIBG radionuclide therapy in carcinoid syndrome

21 January 2018

1 reference

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

21 January 2018

1 reference

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

21 January 2018

1 reference

Neuroblastoma: Therapeutic strategies for a clinical enigma

21 January 2018

1 reference

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

21 January 2018

1 reference

Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine

21 January 2018

1 reference

A kit method for the high level synthesis of [211At]MABG.

21 January 2018

1 reference

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

21 January 2018

1 reference

Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine

21 January 2018

1 reference

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

21 January 2018

1 reference

Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

21 January 2018

1 reference

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma

21 January 2018

1 reference

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

21 January 2018

1 reference

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

21 January 2018

1 reference

Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy

21 January 2018

1 reference

Somatostatin receptor gene expression in neuroblastoma.

21 January 2018

1 reference

Peptide-receptor radionuclide therapy for endocrine tumors

21 January 2018

1 reference

177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma

21 January 2018

1 reference

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors

21 January 2018

1 reference

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

21 January 2018

1 reference

Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue

21 January 2018

1 reference

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

21 January 2018

1 reference

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma

21 January 2018

1 reference

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

21 January 2018

1 reference

Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23196

1 reference

27 August 2017

1 reference